![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | /kæpɪˈsaɪtəbiːn/ |
Trade names | Xeloda, Xitabin, Kapetral, others |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a699003 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Chemotherapy agent |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Extensive |
Protein binding | < 60% |
Metabolism | liver, to 5'-DFCR, 5'-DFUR (inactive); neoplastic tissue, 5'-DFUR to active fluorouracil |
Elimination half-life | 38–45 minutes |
Excretion | Kidney (95.5%), faecal (2.6%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C15H22FN3O6 |
Molar mass | 359.354 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Capecitabine, sold under the brand name Xeloda among others, is a chemotherapy medication used to treat breast cancer, gastric cancer, and colorectal cancer. [1] For breast cancer it is often used together with docetaxel. [2] It is taken by mouth. [2]
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. [2] Other severe side effects include blood clotting problems, allergic reactions, heart problems such as cardiomyopathy, and low blood cell counts. [2] It is not recommended in people with kidney problems. [2] Use during pregnancy may result in harm to the baby. [2] Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. [2] It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur. [4]
Capecitabine was patented in 1992 and approved for medical use in 1998. [5] It is on the World Health Organization's List of Essential Medicines. [6] The wholesale cost in the developing world is about US$122.64–195.66 per cycle of medication. [7] In the United Kingdom it costs the NHS about £210.67 per cycle. [1] In the United States it costs about $1,892.00 as of 2016. [8]
who
was invoked but never defined (see the
help page).
![]() | |
![]() | |
Clinical data | |
---|---|
Pronunciation | /kæpɪˈsaɪtəbiːn/ |
Trade names | Xeloda, Xitabin, Kapetral, others |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a699003 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Chemotherapy agent |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Extensive |
Protein binding | < 60% |
Metabolism | liver, to 5'-DFCR, 5'-DFUR (inactive); neoplastic tissue, 5'-DFUR to active fluorouracil |
Elimination half-life | 38–45 minutes |
Excretion | Kidney (95.5%), faecal (2.6%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C15H22FN3O6 |
Molar mass | 359.354 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Capecitabine, sold under the brand name Xeloda among others, is a chemotherapy medication used to treat breast cancer, gastric cancer, and colorectal cancer. [1] For breast cancer it is often used together with docetaxel. [2] It is taken by mouth. [2]
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. [2] Other severe side effects include blood clotting problems, allergic reactions, heart problems such as cardiomyopathy, and low blood cell counts. [2] It is not recommended in people with kidney problems. [2] Use during pregnancy may result in harm to the baby. [2] Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. [2] It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur. [4]
Capecitabine was patented in 1992 and approved for medical use in 1998. [5] It is on the World Health Organization's List of Essential Medicines. [6] The wholesale cost in the developing world is about US$122.64–195.66 per cycle of medication. [7] In the United Kingdom it costs the NHS about £210.67 per cycle. [1] In the United States it costs about $1,892.00 as of 2016. [8]
who
was invoked but never defined (see the
help page).